October 14, 2016 – Mirada Medical Ltd an international specialist healthcare company, with BTG plc (LSE: BTG), a leading global brand in medical imaging software, today announced it has received CE Mark certification for its new Simplicit90Y™ dosimetry software, designed to optimise the planning of 90Y selective internal radiation therapy (SIRT) and facilitate personalised treatment for patients with liver cancer. CE Mark certification follows approval for Simplicit90Y™ in Canada.

Mirada Medical, in collaboration with BTG, have developed Simplicit90Y™ to be a customised, easy-to-use, dosimetry software developed for rapid 90Y SIRT workflow. Simplicit90Y™ provides digital processing, review and reporting of medical images with unique options for data display, quality control, image manipulation and quantification analysis. Together, these features allow for more standardised and reproducible dosimetry planning and post-treatment validation, and the ability to personalise treatment for each patient.

“Simplicit90Y™ represents an important advance in providing patients and healthcare providers with added value beyond our products and we are pleased to have received CE Mark certification,” commented Zillah Moore, BTG, Director Commercial Operations EMEA. “It will ensure that 90Y therapies, such as TheraSphere®, can be specifically tailored to individual patient needs, facilitating personalised treatments. Simplicit90Y™ will help us offer interventional oncology teams more power to personalise and optimise 90Y SIRT for their patients. We’re delighted Simplicit90Y™ is now available for physicians to use.”

“Dosimetry can be a time intensive and complex process and Simplicit90Y™ simplifies both dosimetry planning and post-treatment validation,” said Etienne Garin, MD, PhD, Chair professor of Nuclear Medicine, Cancer Institute, Centre Eugene Marquis Rennes, France. “Knowing you can use this intuitive software to help deliver a more personalised treatment for each patient, achieving the best dose of 90Y radiation to the tumour while minimising exposure to healthy tissue, gives physicians more confidence.”

Matthieu Leclerc-Chalvet, Mirada Medical, Managing Director commented, “We designed this software to simplify the dosimetry workflow for SIRT and enhance consistency and efficiency. Mirada Medical supports 90Y treatment quality by incorporating advanced image processing tools that facilitate the clinician’s use of multi-modal images to plan 90Y SIRT treatment. Leveraging combined expertise from across the industry helped meeting both the physician’s and patient’s needs and Simplicit90Y™ is a clear demonstration of that success.”

X-Ray Homepage